Page last updated: 2024-12-04

anisindione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

anisindione: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anisindione : A cyclic beta-diketone consisting of indane-1,3-dione having a 4-methoxyphenyl substituent at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2197
CHEMBL ID712
CHEBI ID133809
SCHEMBL ID49379
MeSH IDM0056374

Synonyms (115)

Synonym
2-(4-methoxy-phenyl)-indan-1,3-dione
miradon
smr000146452
MLS000554135 ,
KBIO1_000336
DIVK1C_000336
2-[4-(methyloxy)phenyl]-1h-indene-1,3(2h)-dione
117-37-3
anisindiona [inn-spanish]
1,3-indandione, 2-(p-methoxyphenyl)-
einecs 204-186-6
unidone
brn 1880681
hsdb 3205
anisindionum [inn-latin]
1,3-indanedione, 2-(4-methoxyphenyl)-
spe 2792
SPECTRUM_001355
SPECTRUM5_000960
anisindione
1h-indene-1,3(2h)-dione, 2-(4-methoxyphenyl)-
OPREA1_729452
miradon (tn)
anisindione (inn)
D07457
IDI1_000336
STK363125
andion
2-p-anisyl-1,3-indandione
DB01125
2-(4-methoxyphenyl)indan-1,3-dione
2-(4-methoxyphenyl)-1h-indene-1,3(2h)-dione
anisin indandione
2-para-anisyl-1,3-indandione
2-(p-methoxyphenyl)-1,3-indandione
2-(p-methoxyphenyl)indane-1,3-dione
NCGC00094969-02
NCGC00094969-01
KBIO3_002410
KBIO2_001835
KBIO2_004403
KBIOSS_001835
KBIOGR_000986
KBIO2_006971
SPECTRUM3_001525
SPECTRUM2_000427
SPBIO_000414
SPECTRUM4_000723
NINDS_000336
SPECTRUM1502198
SR-01000642873-1
BSPBIO_002910
MLS001201835
NCGC00094969-03
anisindionum
CHEBI:133809 ,
anisindiona
HMS2092F04
nsc-759629
CHEMBL712 ,
HMS501A18
bdbm50280155
HMS1921L18
2-(4-methoxyphenyl)indene-1,3-dione
AKOS000987728
3-08-00-02931 (beilstein handbook reference)
nsc 759629
s747t1eraj ,
anisindione [inn:ban:nf]
unii-s747t1eraj
pharmakon1600-01502198
nsc759629
tox21_111370
dtxcid102611
dtxsid3022611 ,
cas-117-37-3
HMS2231B10
CCG-40244
FT-0631668
HMS3369M11
gtpl6960
anisindione [mart.]
anisindione [inn]
anisindione [vandf]
anisindione [who-dd]
anisindione [hsdb]
anisindione [mi]
anisindione [orange book]
SCHEMBL49379
NCGC00094969-05
tox21_111370_1
XRCFXMGQEVUZFC-UHFFFAOYSA-N
HY-B0924
OPERA_ID_1613
AB00052289_11
AB00052289_10
2-(4-methoxyphenyl)-2,3-dihydro-1h-indene-1,3-dione
J-003611
SR-01000642873-4
mfcd00176194
SR-01000642873-3
sr-01000642873
SBI-0051739.P002
SW220113-1
Q3617574
E77875
BS-52012
isopropyl n-acetyl-?-d-glucosamine
SY257597
anisindione (mart.)
anisindionum (inn-latin)
unidione
anisindiona (inn-spanish)
EN300-7478363
Z56175413

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anticoagulantAn agent that prevents blood clotting.
vitamin K antagonistA class of anticoagulants which act by inhibiting the action of vitamin K.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
beta-diketoneA diketone in which the two keto groups are separated by a single carbon atom.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Effect of intestinal microbiome on anticoagulant response of vitamin K antagonists413

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.10000.003245.467312,589.2998AID2517
LuciferasePhotinus pyralis (common eastern firefly)Potency4.22420.007215.758889.3584AID1224835; AID588342
RAR-related orphan receptor gammaMus musculus (house mouse)Potency10.01510.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency24.84460.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency26.65140.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency12.60820.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency29.29710.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency12.64290.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency11.12110.001530.607315,848.9004AID1224841; AID1224842; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency22.38720.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.71010.000229.305416,493.5996AID743079
luciferasePhoturis pensylvanica (Pennsylania firefly)Potency11.22020.891310.432820.5750AID1379
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
pyruvate kinaseLeishmania mexicana mexicanaPotency17.78280.398113.744731.6228AID1721; AID1722
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.70790.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency5.62340.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency11.29470.316212.443531.6228AID902; AID924
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency4.46680.001815.663839.8107AID894
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
histone deacetylase 9 isoform 3Homo sapiens (human)Potency24.41260.037617.082361.1927AID1259364; AID1259388
ras-related protein Rab-9AHomo sapiens (human)Potency4.46680.00022.621531.4954AID485297
survival motor neuron protein isoform dHomo sapiens (human)Potency3.98110.125912.234435.4813AID1458
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
Endothelin receptor type BRattus norvegicus (Norway rat)Potency17.78280.562315.160931.6228AID1721
Endothelin-1 receptorRattus norvegicus (Norway rat)Potency17.78280.562315.160931.6228AID1721
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (70)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (186)

Assay IDTitleYearJournalArticle
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID174989Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat LDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109864Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum triglyceride measured on the 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109868Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg orally for Serum triglyceride at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID140306In Vitro evaluation for the CF1 liver enzyme activity on Mitochondrial citrate exchange at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174987Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days against neutral lipids in rat lipoprotein chylomicron1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225244In Vivo effect for the hypolipidemic activity on phosphatidate phosphohydrolase in CF1 mice after 16 days administered orally at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID30374In Vivo effect for the hypolipidemic activity on Acetyl-coenzyme A synthetase in CF1 mice after 16 days of oral administration at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128764In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-CoA carboxylase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128777In Vivo effect for the hypolipidemic activity on Acyl-COA cholesterol acyltransferase in CF1 mice after 16 days of oral administration at a dose of 40 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174996Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on lipid content in rat liver1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175157Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat HDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174994Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat small intestine.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51629In vitro percent Cholesterol 7-alpha-hydroxylase activity in mouse CF1 liver microsomes at 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128770In Vitro evaluation for the CF1 liver enzyme activity on Hepatic lipoprotein lipase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225241In Vivo effect for the hypolipidemic activity on phosphatidate phosphohydrolase in CF1 mice after 16 days administered orally at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175003Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on neutral lipids content in rat small intestine.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128779In Vivo effect for the hypolipidemic activity on Hepatic lipoprotein lipase in CF1 mice after 16 days administered orally at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175165Compound was evaluated for the hypolipidemic activity in Sprague-Dawley rats at a dose of 20 mg/kg orally for Serum cholesterol at 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID30373In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-coenzyme A synthetase at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175158Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat LDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175160Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat feces.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175167Compound was evaluated for the hypolipidemic activity in Sprague-Dawley rats at a dose of 20 mg/kg orally for Serum triglyceride at 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128772In Vivo effect for the hypolipidemic activity on Acetyl-CoA carboxylase in CF1 mice after 16 days administered orally at a dose of 40 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128778In Vivo effect for the hypolipidemic activity on Acyl-COA cholesterol acyltransferase in CF1 mice after 16 days of oral administration at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175006Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on phospholipids content in rat VLDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226353In Vivo effect for the hypolipidemic activity on sn-glycerol-3-phosphate acyltransferase in CF1 mice after 16 days administered orally at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175001Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on neutral lipids content in rat VLDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226352In Vitro evaluation for the CF1 liver enzyme activity on sn-glycerol-3-phosphate acyltransferase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109860Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg orally for Serum cholesterol at 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175150Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat HDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174993Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat liver1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174998Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on neutral lipid content in rat liver1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175159Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat VLDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51627In vitro percent Cholesterol 7-alpha-hydroxylase activity in mouse CF1 liver microsomes at 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32383In Vitro evaluation for the CF1 liver enzyme activity on ATP-Citrate Lyase exchange at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51628In vitro percent Cholesterol 7-alpha-hydroxylase activity in mouse CF1 liver microsomes at 200 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226355In Vivo effect for the hypolipidemic activity on sn-glycerol-3-phosphate acyltransferase in CF1 mice after 16 days administered orally at a dose of 40 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175151Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat LDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175154Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat lipoprotein chylomicron1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83313In Vivo effect for the hypolipidemic activity on HMG-CoA reductase in CF1 mice after 16 days of oral administration at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83309In Vitro evaluation for the CF1 liver enzyme activity on HMG CoA reductase at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226350In Vitro evaluation for the CF1 liver enzyme activity on sn-glycerol-3-phosphate acyltransferase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174997Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on lipid content in rat small intestine.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174992Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat lipoprotein chylomicron1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID109867Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg orally for Serum cholesterol at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID31038In Vitro evaluation for the CF1 liver enzyme activity on Acyl cholesterol acyltransferase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128769In Vitro evaluation for the CF1 liver enzyme activity on Hepatic lipoprotein lipase at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109872Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 60 mg/kg orally for Serum cholesterol at 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32385In Vivo effect for the hypolipidemic activity on ATP-Citrate Lyase in CF1 mice after 16 days administered orally at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID140305In Vitro evaluation for the CF1 liver enzyme activity on Mitochondrial citrate exchange at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175153Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat feces.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128768In Vitro evaluation for the CF1 liver enzyme activity on Hepatic lipoprotein lipase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225239In Vitro evaluation for the CF1 liver enzyme activity on phosphatidate phosphohydrolase at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83312In Vivo effect for the hypolipidemic activity on HMG-CoA reductase in CF1 mice after 16 days of oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109871Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 40 mg/kg orally for Serum triglyceride at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175000Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on neutral lipids content in rat LDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83315In Vivo effect for the hypolipidemic activity on HMG-CoA reductase in CF1 mice after 16 days of oral administration at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175005Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on phospholipids content in rat LDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83310In Vitro evaluation for the CF1 liver enzyme activity on HMG-CoA reductase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174995Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on lipid content in rat feces.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51630In vivo effect on Cholesterol 7-alpha-hydroxylase activity in CF1 mice after 16 days at 10 mg/kg oral dose1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174999Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on neutral lipids content in rat HDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225238In Vitro evaluation for the CF1 liver enzyme activity on phosphatidate phosphohydrolase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174990Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat VLDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109861Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum cholesterol measured on the 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51632In vivo effect on Cholesterol 7-alpha-hydroxylase activity in CF1 mice after 16 days at 40 mg/kg oral dose1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128774In Vivo effect for the hypolipidemic activity on Acetyl-coenzyme A synthetase in CF1 mice after 16 days of oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175161Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat lipoprotein chylomicron; p1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175164Compound was evaluated for the hypolipidemic activity in Sprague-Dawley rats at a dose of 20 mg/kg orally for Serum cholesterol at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID30372In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-coenzyme A synthetase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109863Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum cholesterol measured on the 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32381In Vitro evaluation for the CF1 liver enzyme activity on ATP-Citrate Lyase exchange at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175002Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on neutral lipids content in rat feces.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128782In Vivo effect for the hypolipidemic activity on Hepatic lipoprotein lipase in CF1 mice after 16 days administered orally at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109857Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 10 mg/kg orally for Serum cholesterol at 9th day.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109858Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 10 mg/kg orally for Serum cholesterol at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128781In Vivo effect for the hypolipidemic activity on Hepatic lipoprotein lipase in CF1 mice after 16 days administered orally at a dose of 40 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID30366In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-CoA carboxylase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51631In vivo effect on Cholesterol 7-alpha-hydroxylase activity in CF1 mice after 16 days at 20 mg/kg oral dose1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID30375In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-coenzyme A synthetase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID30367In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-CoA carboxylase at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID1136511Uncoupling activity of oxidative phosphorylation in rat liver mitochondria1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID174991Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat feces.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128776In Vivo effect for the hypolipidemic activity on Acyl-COA cholesterol acyltransferase in CF1 mice after 16 days of oral administration at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83314In Vivo effect for the hypolipidemic activity on HMG-CoA reductase in CF1 mice after 16 days of oral administration at a dose of 40 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109869Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 40 mg/kg orally for Serum cholesterol at 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226356In Vivo effect for the hypolipidemic activity on sn-glycerol-3-phosphate acyltransferase in CF1 mice after 16 days administered orally at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128771In Vivo effect for the hypolipidemic activity on Acetyl-CoA carboxylase in CF1 mice after 16 days administered orally at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175156Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat small intestine.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175149Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on phospholipids content in rat lipoprotein chylomicron1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128775In Vivo effect for the hypolipidemic activity on Acyl-COA cholesterol acyltransferase in CF1 mice after 16 days of oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128767In Vitro evaluation for the CF1 liver enzyme activity on Acyl cholesterol acyltransferase at concentration 200 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID140304In Vitro evaluation for the CF1 liver enzyme activity on Mitochondrial citrate exchange at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109870Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 40 mg/kg orally for Serum cholesterol at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID109859Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 10 mg/kg orally for Serum triglyceride at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109873Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 60 mg/kg orally for Serum cholesterol at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID51633In vivo effect on Cholesterol 7-alpha-hydroxylase activity in CF1 mice after 16 days at 60 mg/kg oral dose1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225240In Vitro evaluation for the CF1 liver enzyme activity on phosphatidate phosphohydrolase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128773In Vivo effect for the hypolipidemic activity on Acetyl-CoA carboxylase in CF1 mice after 16 days administered orally at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128780In Vivo effect for the hypolipidemic activity on Hepatic lipoprotein lipase in CF1 mice after 16 days administered orally at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32386In Vivo effect for the hypolipidemic activity on ATP-Citrate Lyase in CF1 mice after 16 days of oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175162Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat liver1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32384In Vitro evaluation for the CF1 liver enzyme activity on ATP-dependent citrate exchange at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109874Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 60 mg/kg orally for Serum triglyceride at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID125447In Vivo effect for the hypolipidemic activity on Acetyl-coenzyme A synthetase in CF1 mice after 16 days of oral administration at a dose of 60 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175155Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat liver1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128766In Vitro evaluation for the CF1 liver enzyme activity on Acyl cholesterol acyltransferase at concentration 100 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID128765In Vitro evaluation for the CF1 liver enzyme activity on Acetyl-CoA synthetase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226354In Vivo effect for the hypolipidemic activity on sn-glycerol-3-phosphate acyltransferase in CF1 mice after 16 days administered orally at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175148Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on phospholipids content in rat small intestine.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID226351In Vitro evaluation for the CF1 liver enzyme activity on sn-glycerol-3-phosphate acyltransferase at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175004Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on phospholipids content in rat HDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225243In Vivo effect for the hypolipidemic activity on phosphatidate phosphohydrolase in CF1 mice after 16 days administered orally at a dose of 40 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32382In Vitro evaluation for the CF1 liver enzyme activity on ATP-Citrate Lyase exchange at concentration 200 uM 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID175152Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on protein content in rat VLDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID174988Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on cholesterol content in rat HDL1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175163Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on triglycerides content in rat small intestine.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID83311In Vitro evaluation for the CF1 liver enzyme activity on HMG-CoA reductase at concentration 50 uM1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175166Compound was evaluated for the hypolipidemic activity in Sprague-Dawley rats at a dose of 20 mg/kg orally for Serum triglyceride at 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID30368In Vivo effect for the hypolipidemic activity on Acetyl-CoA carboxylase in CF1 mice after 16 days administered orally at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID32387In Vivo effect for the hypolipidemic activity on ATP-Citrate Lyase in CF1 mice after 16 days of oral administration at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID225242In Vivo effect for the hypolipidemic activity on phosphatidate phosphohydrolase in CF1 mice after 16 days administered orally at a dose of 20 mg/kg1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID175147Compound was evaluated for the hypolipidemic activity at 20 mg/kg per day orally for 14 days on phospholipids content in rat feces.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (37.14)18.7374
1990's1 (2.86)18.2507
2000's2 (5.71)29.6817
2010's13 (37.14)24.3611
2020's6 (17.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.37 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.86%)6.00%
Case Studies2 (5.71%)4.05%
Observational0 (0.00%)0.25%
Other32 (91.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]